Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

To report the results of the DECT trial, a phase II study of locally advanced or operable HER2‐positive breast cancer (BC) treated with taxanes and concurrent anthracyclines and trastuzumab. Eligible patients (stage IIA‐IIIB HER2‐positive BC, 18–75 years, normal organ functions, ECOG ≤1, and left ve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Physiol
Main Authors: Pizzuti, Laura, Barba, Maddalena, Giannarelli, Diana, Sergi, Domenico, Botti, Claudio, Marchetti, Paolo, Anzà, Michele, Maugeri‐Saccà, Marcello, Natoli, Clara, Di Filippo, Simona, Catenaro, Teresa, Tomao, Federica, Amodio, Antonella, Carpano, Silvia, Perracchio, Letizia, Mottolese, Marcella, Di Lauro, Luigi, Sanguineti, Giuseppe, Di Benedetto, Anna, Giordano, Antonio, Vici, Patrizia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089631/
https://ncbi.nlm.nih.gov/pubmed/27187274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.25432
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados